Gene · 1890
Papers4,467
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
261 to 280 of 4,467
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Clinical Effect of the C-Reactive Protein to Serum Albumin Ratio in Patients with Metastatic Gastric or Gastroesophageal Junction Cancer Treated with Trifluridine/Tipiracil. | J Pers Med | 2023 | 37373912 | PubTator, text mining | PubMed |
| Prognostic Impact of Dihydropyrimidine Dehydrogenase Germline Variants in Unresectable Non-Small Cell Lung Cancer Patients Treated with Platin-Based Chemotherapy. | Int J Mol Sci | 2023 | 37372990 | PubTator, text mining | PubMed |
| Gender Differences in Oxidative Stress in Relation to Cancer Susceptibility and Survival. | Antioxidants (Basel) | 2023 | 37371985 | PubTator, text mining | PubMed |
| Update on Classic and Novel Approaches in Metastatic Triple-Negative Breast Cancer Treatment: A Comprehensive Review. | Biomedicines | 2023 | 37371867 | PubTator, text mining | PubMed |
| Gastric Cancer Vascularization and the Contribution of Reactive Oxygen Species. | Biomolecules | 2023 | 37371466 | PubTator, text mining | PubMed |
| Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study. | Curr Oncol | 2023 | 37366896 | PubTator, text mining | PubMed |
| A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series. | Curr Oncol | 2023 | 37366880 | PubTator, text mining | PubMed |
| Review on Isatin- A Remarkable Scaffold for Designing Potential Therapeutic Complexes and Its Macrocyclic Complexes with Transition Metals. | J Inorg Organomet Polym Mater | 2023 | 37359385 | PubTator, text mining | PubMed |
| Multifunctional role of thymidine phosphorylase in cancer: (Trends in Cancer, 8:6 p:482-493, 2022). | Trends Cancer | 2023 | 37355411 | PubTator, text mining | PubMed |
| Metronomic capecitabine inhibits liver transplant rejection in rats by triggering recipients' T cell ferroptosis. | World J Gastroenterol | 2023 | 37346150 | PubTator, text mining | PubMed |
| Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma. | Oncologist | 2023 | 37339254 | PubTator, text mining | PubMed |
| Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil. | J Cancer Res Clin Oncol | 2023 | 37318592 | PubTator, text mining | PubMed |
| Pontine stroke in a patient with Chronic Progressive External Ophthalmoplegia (CPEO): a case report. | BMC Neurol | 2023 | 37316776 | PubTator, text mining | PubMed |
| Comprehensive and deep profiling of the plasma proteome with protein corona on zeolite NaY. | J Pharm Anal | 2023 | 37305782 | PubTator, text mining | PubMed |
| Proteomic and Metabolomic Changes in Psoriasis Preclinical and Clinical Aspects. | Int J Mol Sci | 2023 | 37298466 | PubTator, text mining | PubMed |
| A Multi-Omics Overview of Colorectal Cancer to Address Mechanisms of Disease, Metastasis, Patient Disparities and Outcomes. | Cancers (Basel) | 2023 | 37296894 | PubTator, text mining | PubMed |
| Antiviral activities of two nucleos(t)ide analogs against vaccinia, mpox, and cowpox viruses in primary human fibroblasts. | Antiviral Res | 2023 | 37270160 | PubTator, text mining | PubMed |
| Vaccine-induced immune thrombotic thrombocytopenia: what do we know hitherto? | Front Med (Lausanne) | 2023 | 37261122 | PubTator, text mining | PubMed |
| An Understanding of Mechanism-Based Approaches for 1,3,4-Oxadiazole Scaffolds as Cytotoxic Agents and Enzyme Inhibitors. | Pharmaceuticals (Basel) | 2023 | 37259401 | PubTator, text mining | PubMed |
| Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm? | Front Pharmacol | 2023 | 37256234 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1890/papers?page=14